NILOTINIB 400 MG BID DAILY AS FRONTLINE THERAPY OF PH plus CHRONIC MYELOID LEUKEMIA: DOSE DELIVERY AND SAFETY PROFILE AT 2 YEARS

被引：0

作者：

Castagnetti, F. ^{[1
]}

Palandri, F. ^{[1
]}

Breccia, M. ^{[2
]}

Levato, L. ^{[3
]}

Capucci, A. ^{[4
]}

Tiribelli, M. ^{[5
]}

Zaccaria, A. ^{[6
]}

Bocchia, M. ^{[7
]}

Cuneo, A. ^{[8
]}

Stagno, F. ^{[9
]}

Specchia, G. ^{[10
]}

Musso, M. ^{[11
]}

Gugliotta, G. ^{[1
]}

Testoni, N. ^{[1
]}

Alimena, G. ^{[2
]}

Pane, F. ^{[12
]}

Martinelli, G. ^{[1
]}

Saglio, G. ^{[13
]}

Baccarani, M. ^{[1
]}

Rosti, G. ^{[1
]}

机构：

[1] Univ Bologna, Dpt Hematol & Oncol Seragnoli, Bologna, Italy

[2] Univ Roma La Sapienza, Dept Biotechnol & Hematol, Rome, Italy

[3] A Pugliese Hosp, Hematol Unit, Catanzaro, Italy

[4] Spedali Civil Brescia, Hematol Unit, I-25125 Brescia, Italy

[5] Univ Udine, Dept Med & Morphol Res, I-33100 Udine, Italy

[6] Ravenna Hosp, Hematol Unit, Ravena, Italy

[7] Univ Siena, Dept Hematol, I-53100 Siena, Italy

[8] Univ Ferrara, Dept Hematol, I-44100 Ferrara, Italy

[9] Univ Catania, Dept Biomed Sci, Catania, Italy

[10] Univ Bari, Dept Hematol, Bari, Italy

[11] La Madalena Hosp, Hematol & Bone Marrow Transplantat Unit, Palermo, Italy

[12] Univ Naples Federico II, Dept Biochem & Med Biotechnol, Naples, Italy

[13] Univ Turin, Dpt Clin & Biol Sci, Orbassano, Italy

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0814

引用

页码：340 / 341

页数：2

共 50 条

[41] NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY
O'Dwyer, E.
Swords, R.
Giles, F.
LeCoutre, P.
McMullin, M.
Langabeer, S.
Padmanabhan, S.
Kent, E.
Parker, M.
Moulton, B.
Egan, K.
Conneally, E.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 340 - 340
[42] Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study
O'Dwyer, Michael C.
Kent, Emma
Parker, Michael
Swords, Ronan T.
Giles, Frank
le Coutre, Philipp
Padmanabhan, Swaminathan
Moulton, Brian
McMullin, Mary Frances
Langabeer, Stephen
Egan, Karine
Conneally, Eibhlin
BLOOD, 2009, 114 (22) : 1277 - 1277
[43] NILOTINIB 800 MG DAILY IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: 12-MONTHS RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
Rosti, G.
Castagnetti, F.
Breccia, M.
Poerio, A.
Gugliotta, G.
Levato, L.
Palandri, F.
Capucci, A.
Tiribelli, M.
Stagno, F.
Marzocchi, G.
Luatti, S.
Amabile, M.
Zaccaria, A.
Alimena, G.
Pane, F.
Martinelli, G.
Saglio, G.
Baccarani, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 440 - 440
[44] NILOTINIB 800 MG DAILY AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN EARLY CHRONIC PHASE: RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
Rosti, G.
Castagnetti, E.
Palandri, E.
Breccia, M.
Levato, L.
Capucci, A.
Tiribelli, M.
Alimena, G.
Stagno, F.
Rondoni, M.
Alberti, D.
Marzocchi, G.
Luatti, S.
Amabile, M.
Poerio, A.
Martinelli, G.
Pane, F.
Saglio, G.
Baccarani, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 161 - 161
[45] Effect of increasing imatinib mesylate (STI571) dose from 400 mg to 800 mg daily on outcome of patients (pts) with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph plus CML CP).
Kantarjian, HM
Cortes, J
O'Brien, S
Rios, MB
Shan, J
Capdeville, R
Talpaz, M
BLOOD, 2001, 98 (11) : 137A - 137A
[46] Modelling BCR-ABL1 Dynamics in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) during Frontline Therapy with High-Dose Imatinib, Nilotinib, or Dasatinib
Olshen, Adam
Quintas-Cardama, Alfonso
Kantarjian, Hagop M.
Gonen, Mithat
Michor, Franziska
Cortes, Jorge
BLOOD, 2008, 112 (11) : 1113 - 1113
[47] Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307
Rosti, Gianantonio
Gugliotta, Gabriele
Castagnetti, Fausto
Breccia, Massimo
Levato, Luciano
Rege-Cambrin, Giovanna
Capucci, Adele
Tiribelli, Mario
Zaccaria, Alfonso
Bocchia, Monica
Stagno, Fabio
Cavazzini, Francesco
Specchia, Giorgina
Martino, Bruno
Cedrone, Michele
Intermesoli, Tamara
Palandri, Francesca
Soverini, Simona
Bochicchio, Maria Teresa
Testoni, Nicoletta
Alimena, Giuliana
Pane, Fabrizio
Saglio, Giuseppe
Martinelli, Giovanni
Baccarani, Michele
BLOOD, 2012, 120 (21)
[48] NILOTINIB (TASIGNA) THERAPY POST ALLOGENEIC STEM CELL TRANSPLANTATION (ALLoSCT) FOR ADVANCED (>CP1) CHRONIC MYELOID LEUKEMIA (CML) AND PH plus ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Nagler, A.
Volchek, Y.
Varda-Bloom, N.
Somech, R.
Yerushalmi, R.
Shimoni, A.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S365 - S365
[49] Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
Hiwase, Devendra
Tan, Peter
D'Rozario, James
Taper, John
Powell, Anthony
Irving, Ian
Wright, Matthew
Branford, Susan
Yeung, David T.
Anderson, Luke
Gervasio, Othon
Levetan, Carly
Roberts, Will
Solterbeck, Ann
Traficante, Robert
Hughes, Timothy
LEUKEMIA RESEARCH, 2018, 67 : 109 - 115
[50] A PROSPECTIVE RANDOMIZED STUDY OF IMATINIB 400 MG VS 800 MG AS A FRONT-LINE THERAPY IN HIGH SOKAL RISK PH-POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE
Rosti, G.
Castagnetti, F.
Haznedaroglu, I
Porkka, K.
Nielsen, J. L.
Hjorth-Hansen, H.
Rege-Cambrin, G.
Specchia, G.
Amabile, M.
Testoni, N.
Palandri, F.
Iacobucci, I.
Soverini, S.
Pane, F.
Alimena, G.
Martinelli, G.
Russo, D.
Saglio, G.
Simonsson, B.
Baccarani, M.
HAEMATOLOGICA, 2008, 93 : S60 - S60

← 1 2 3 4 5 →